MESSAGE TO OUR
      VOLUNTEERS



Our foundation is perhaps the most worthy to work for: Each step toward its objectives will have impact on improving the health of the nation. We need individuals dedicated to fighting cardiovascular disease or cancer, working from home, contacting our sponsors, helping us move forward.

Your assistance will be greatly appreciated. At the same time, you will learn precious skills and experience in working for medical research organizations, and one day may become our full-time employee devoted to exciting advancements on the biggest issues in human health. For information, email us at ContactUs@heartFirst.org, or call (775) 201-5711

Vascular Research Foundation (VRF) is a non-profit organization dedicated to medical research with 501(c)3 status (pending). We are uniquely focused on the major threats to human health. VRF’s purpose is to support cutting-edge investigations advancing our knowledge concerning the causes, prevention and treatment of vascular conditions (cardiovascular disease, also the cancer vascularization) using state-of-the-art technologies. VRF sponsors innovative studies that will produce accelerated treatments for vascular system diseases that lead to myocardial infarction, stroke and tumor development. The founder is affiliated with leading U.S. medical centers that will host the investigations.

Generally, there are three medical practices related to a disease: prevention, diagnosis and treatment. Working on all of them would require significant resources. Notably, the lead investigator and his teams have projects under way to address each of these stages of fighting the main target, cardiovascular disease. The Vascular Research Foundation therefore plays a vital role in accelerating the work to advance medical science and benefit the patients.

 

The central approach in our investigations of cardiovascular disease, atherosclerotic inflammations, is already being recognized and is built on the presence of inflammatory agents in the vascular wall of large vessels (aortic, carotid, femoral) leading to initiation, growth, and – most importantly – destabilization of the atheromatous tissue that is the actual event leading to ischemia (myocardial infarction and stroke). The Lead Investigator works in this fast developing area with world-class facilities at leading institutions, Columbia and Cornell Medical Centers in New York as well as at University of Florida,in addition to the laboratories of the collaborating investigators across the nation.

In addition, our approach in fighting cancer is based on an entirely new mechanism of angiosuppression (blocking of tumor vasculature). The preclinical trials are encouraging, demonstrating tumor tissue necrosis and (in latest trials) tumor growth retardation of 40%, although using only minimal treatment dose. The data strongly support our goal to carry on the development of our new class of angiosuppressive agents for the benefit of cancer patients.